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Abstract 
  
Major effectors of adult-stage fetal globin silencing include the transcription factors (TFs) 
BCL11A and ZBTB7A/LRF and the NuRD chromatin complex, although each has potential on-
target liabilities for rational 𝛽-hemoglobinopathy therapeutic inhibition. Here through CRISPR 
screening we discover ZNF410 to be a novel fetal hemoglobin (HbF) repressing TF. ZNF410 
does not bind directly to the 𝛾-globin genes but rather its chromatin occupancy is solely 
concentrated at CHD4, encoding the NuRD nucleosome remodeler, itself required for HbF 
repression. CHD4 has two ZNF410-bound regulatory elements with 27 combined ZNF410 
binding motifs constituting unparalleled genomic clusters. These elements completely account 
for ZNF410’s effects on 𝛾-globin repression. Knockout of ZNF410 reduces CHD4 by 60%, 
enough to substantially de-repress HbF while avoiding the cellular toxicity of complete CHD4 
loss. Mice with constitutive deficiency of the homolog Zfp410 are born at expected Mendelian 
ratios with unremarkable hematology. ZNF410 is dispensable for human hematopoietic 
engraftment potential and erythroid maturation unlike known HbF repressors. These studies 
identify a new rational target for HbF induction for the 𝛽-hemoglobin disorders with a wide 
therapeutic index. More broadly, ZNF410 represents a special class of gene regulator, a 
conserved transcription factor with singular devotion to regulation of a chromatin subcomplex.  
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Introduction 1 
  2 
Despite renewed enthusiasm for novel approaches to 𝛽-hemoglobinopathies, the clinical unmet 3 
need for these most common monogenic diseases remains vast1–3. Induction of fetal 𝛾-globin 4 
gene expression could bypass the underlying 𝛽-globin molecular defects and ameliorate the 5 
pathophysiological cascades that result in elevated morbidity and mortality. Critical regulators of 6 
the switch from fetal to adult globin gene expression include the DNA-binding transcription 7 
factors (TFs) BCL11A and ZBTB7A and the nucleosome remodeling and deacetylase (NuRD) 8 
chromatin complex4–7. BCL11A and ZBTB7A each bind to unique sites at the proximal 9 
promoters of the duplicated fetal 𝛾-globin genes HBG1 and HBG2 and each physically interact 10 
with NuRD5,8–10. Although the molecular details underpinning this switch, including the precise 11 
sequences bound and NuRD subcomplex members required, are increasingly understood, still 12 
the feasibility to directly perturb these mechanisms through pharmacology remains uncertain. 13 
One challenge is the pleiotropic molecular, cellular and organismal effects of each of the 14 
aforementioned fetal hemoglobin (HbF) repressors which makes the therapeutic window 15 
uncertain and the risk of undesired on-target liabilities considerable. An ideal target would have 16 
a wide therapeutic index through which inhibition of function could be tolerated across a diverse 17 
set of cellular contexts.  18 
 19 
To better define additional molecular players orchestrating the developmental regulation of 20 
globin gene expression, we performed a CRISPR screen focusing on putative DNA-binding TFs 21 
that contribute to HbF silencing. We identified ZNF410 as a novel DNA-binding TF required for 22 
HbF repression. Little was previously known about ZNF410. We show indeed this gene is 23 
required for HbF silencing. Surprisingly we find that it displays a narrowly restricted pattern of 24 
chromatin occupancy, not binding to the globin locus directly, but rather binding to upstream 25 
elements, through an unusual set of clustered motifs, controlling the expression of the catalytic 26 
NuRD subunit CHD4. We observe that ZNF410 and its mouse homolog Zfp410 are dispensable 27 
for survival to adulthood as well as normal erythropoiesis and hematopoietic repopulation.   28 
   29 
 30 
 31 
 32 
 33 
 34 
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Results 35 
  36 
CRISPR screen for novel transcriptional regulators of HbF level 37 
  38 
We performed a CRISPR screen in a primary human erythroid precursor cell line (HUDEP-2) 39 
that expresses an adult-type pattern of globins to discover genes required for repression of HbF. 40 
The screen targeted 1591 transcription factors and 13 genes of the NuRD complex as controls. 41 
HUDEP-2 cells stably expressing SpCas9 were first generated. HUDEP-2/Cas9 cells were then 42 
transduced by the sgRNA library at low multiplicity and selected for sgRNA cassette integration 43 
by acquisition of puromycin resistance. Following erythroid maturation culture, cells were 44 
stained for HbF expression and HbF+ cells (range 1.8-7%) selected by FACS (Fig. 1a). 45 
Integrated sgRNAs were amplified from genomic DNA and counted by deep sequencing. We 46 
calculated two sgRNA enrichment scores. First, sgRNA abundance was compared in HbF+ and 47 
total cells at the end of erythroid maturation to obtain an HbF enrichment score. Second, sgRNA 48 
abundance was compared in cells at the end of erythroid maturation and the starting library to 49 
define a cell fitness score. Negative cell fitness scores indicate relative depletion whereas 50 
positive scores indicate relative enrichment of cells bearing these sgRNAs.   51 
  52 
As expected, we found that known HbF regulators like BCL11A and ZBTB7A showed highly 53 
elevated HbF enrichment scores (Fig. 1b). For BCL11A we observed a modest negative fitness 54 
score, suggesting that loss of this gene had a modest negative impact on cell accumulation in 55 
vitro. For ZBTB7A we observed a positive fitness score, suggesting cells mutated at this gene 56 
accumulated in the population, consistent with its known requirement for terminal erythroid 57 
maturation11. In addition, we validated prior findings that a NuRD subcomplex including CHD4, 58 
MTA2, GATAD2A, MBD2, and HDAC2 was required for HbF control6. Editing CHD4 led to 59 
potent HbF induction but was associated with negative cell fitness. 60 
  61 
We observed sgRNAs targeting ZNF410 were associated with robust HbF induction (Fig. 1b). 62 
Unlike other regulators like BCL11A, ZBTB7A, and CHD4, we observed no fitness effects of 63 
targeting ZNF410. Relatively few prior studies have investigated ZNF410, encoding a zinc finger 64 
protein with a cluster of five C2H2 zinc fingers. It has not been previously implicated in globin 65 
gene regulation or erythropoiesis. One previous study indicated that over-expression of ZNF410 66 
in human foreskin fibroblasts led to increased expression of matrix remodeling genes MMP1, 67 
PAI2 and MMP12 and ZNF410 sumoylation extended its half-life12. The biochemical functions 68 
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and biological roles of endogenous ZNF410 remain largely unexplored. Therefore we focused 69 
on ZNF410 as a potentially novel regulator of HbF. 70 
 71 
Validation in HUDEP-2 cells and primary adult erythroid precursors 72 
 73 
We first tested the role of ZNF410 in HbF repression by targeting it in HUDEP-2 cells with 74 
individual gRNAs. Upon editing in a bulk population of cells, we found induction of HbF, as 75 
measured by HbF+ cells by intracellular flow cytometry, HBG1/2 expression by RT-qPCR, and 76 
HbF induction by HPLC (Fig. 1c). We generated 3 single cell derived HUDEP-2 ZNF410 77 
biallelic KO clones. In each clone, the fraction of HbF+ cells was elevated. Upon re-expression 78 
of ZNF410, HbF was partially silenced, consistent with a causal role of ZNF410 in repressing 79 
HbF (Fig. 1d).    80 
 81 
We next examined the role of ZNF410 in HbF repression in primary erythroblasts derived from 82 
erythroid culture of adult mobilized peripheral blood CD34+ HSPCs. Using cells from 3 83 
independent donors, we found that targeting ZNF410 by 3xNLS-SpCas9:sgRNA RNP 84 
electroporation produced >99% indels with a +1 insertion allele (Fig. 1e). ZNF410 targeted 85 
erythroblasts displayed normal erythroid maturation based on immunophenotype and 86 
enucleation, yet robust induction of HbF from a median of 5.5% in mock to 21.1% in ZNF410 87 
targeted samples (Fig. 1e, p<0.0001).  88 
 89 
ZNF410 is a DNA-binding protein with highly restricted chromatin occupancy 90 
 91 
We performed dense mutagenesis of ZNF410 to identify critical minimal sequences required for 92 
function. In this experimental design, heightened HbF enrichment scores indicate sequences 93 
where not only frameshift but also in-frame mutations may be associated with loss-of-function6. 94 
We observed heightened HbF enrichment scores especially when targeting sequences from 95 
exons 6-9 encoding the cluster of five C2H2 zinc fingers of ZNF410 (Fig. 2a). This dependence 96 
on its putative DNA binding domain suggested that the DNA-binding function of ZNF410 might 97 
be important for its role in HbF repression. 98 
  99 
We examined the chromatin occupancy of ZNF410 by conducting CUT&RUN, an approach to 100 
studying protein-DNA interactions in situ without fragmentation or cross-linking13. Initially we 101 
used an HA antibody to probe for epitope tagged ZNF410 in HUDEP-2 cells. Known HbF 102 
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repressing TFs like BCL11A and ZBTB7A act by binding to proximal promoter elements at the 103 
fetal 𝛾-globin (HBG1 and HBG2) genes. We did not observe any chromatin occupancy of 104 
ZNF410 at the 𝛼-globin (HBA1 and HBA2) or 𝛽-globin (HBB) gene clusters (Supp. Fig. 1a, b). 105 
Unlike typical DNA binding transcription factors which show thousands of binding sites genome 106 
wide, ZNF410 showed highly restricted chromatin occupancy. With standard peak calling 107 
parameters, we found 49 peaks, but most of these had marginal enrichment of ZNF410-HA 108 
signal compared to an IgG control. The top two peaks were found at the CHD4 locus, one at the 109 
promoter (57-fold enrichment) and the other 6 kb upstream at a region of open chromatin (77-110 
fold enrichment, Fig. 2b, 2d). This latter element we subsequently refer to as the CHD4 -6 kb 111 
enhancer. The third most enriched peak was in CHD4 intron 2, with ~10 fold enrichment (Fig. 112 
2b, 2d). The fourth most enriched peak was in TIMELESS intron 1, with ~10 fold enrichment, 113 
around accessible chromatin at sequences bearing an LTR element (Fig. 2b, Supp. Fig. 2a).  114 
 115 
Subsequently we used a ZNF410 antibody to probe for endogenous ZNF410 with CUT&RUN, 116 
both in HUDEP-2 cells and in CD34+ HSPC derived erythroid precursors (Fig. 2d). In both 117 
cases, we found that ZNF410 chromatin occupancy was highly restricted to CHD4. In HUDEP-2 118 
cells, only 5 total peaks were identified, the top 4 of which were at the CHD4 promoter and 119 
CHD4 -6 kb enhancer (Fig. 2d, Supp. Fig. 2b). The 5th peak was at intronic sequences of 120 
DPY19L3 bearing an LTR element (5-fold enrichment) (Supp. Fig. 2d). In CD34+ HSPC-121 
derived erythroid precursors, only 5 total peaks were identified, all of which were at the CHD4 122 
promoter or CHD4 -6 kb enhancer, with no other genomic sites of ZNF410 occupancy found 123 
(Fig. 2d, Supp. Fig. 2c).  124 
 125 
The ZNF410 binding motif has previously been described by high-throughput SELEX using 126 
expression of the DNA-binding domain in 293FT cells14. We observed a striking cluster of these 127 
motifs at CHD4, with numerous motif instances found at both the promoter (16 motifs) and the -128 
6 kb enhancer (11 motifs, Fig. 2c, d). We scanned the genome for the ZNF410 binding motif, 129 
dividing the genome into 3 kb windows. 4306 genomic windows had 1 motif instance and 16 130 
windows had 2 motif instances (Fig. 2c). Only 3 windows had more than 2 motif instances, of 131 
which 2 were the aforementioned CHD4 elements. We observed 6 motif instances within a 132 
window at GALNT18 intron 1, although we observed neither ZNF410 occupancy nor chromatin 133 
accessibility at this locus in erythroid precursors (Supp. Fig. 1c).  134 
  135 
 136 
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ZNF410 regulates HbF through CHD4 137 
 138 
These results suggested that ZNF410 exhibits singular binding to CHD4. We performed RNA-139 
seq of HUDEP-2 cells edited at ZNF410 to measure gene expression changes (Fig. 3a). Based 140 
on log2 fold change >1 and adjusted p-value <0.01, there were 63 differentially expressed 141 
genes. CHD4 was the most significantly downregulated gene upon ZNF410 editing (L2FC -1.07, 142 
padj 2.27x10-43). HBG2 was the 4th most significantly upregulated gene (L2FC 2.35, padj 5.93x10-143 
25). Gene set enrichment analysis showed that genes differentially expressed after ZNF410 144 
editing were enriched in those differentially expressed after CHD4 editing (for upregulated 145 
genes, NES 1.61, q 0.05; for downregulated genes, NES -1.39, q 0.09; Fig. 3b, Supp. Fig. 3a). 146 
The expression of ZNF410 and CHD4 were significantly correlated across 54 human tissues 147 
from the GTEx dataset15 (Supp. Fig. 3b, Pearson correlation, r 0.77, p<0.0001). We evaluated 148 
a repository of genome-wide CRISPR KO screen data spanning 558 cell lines to identify genes 149 
with a similar pattern of cellular dependency as ZNF41016,17. We found that CHD4 was the most 150 
similarly codependent gene across cell lines, indicating a pervasive relationship between 151 
ZNF410 and CHD4 (Fig. 3c). These results suggest that a major function of ZNF410 across 152 
numerous cellular contexts appears to be control of CHD4 expression.  153 
 154 
We validated the changes in CHD4 expression after ZNF410 editing by RT-qPCR in both 155 
HUDEP-2 cells and primary erythroid precursors derived from CD34+ HSPCs. We found that 156 
CHD4 mRNA expression was reduced by 57% after ZNF410 editing (Fig. 3d, p<0.01). To test 157 
the requirement of ZNF410 binding for CHD4 expression, we generated HUDEP-2 cell clones in 158 
which the two upstream ZNF410 motif clusters at CHD4 were both deleted by paired genomic 159 
cleavages (Fig. 3e, Supp. Fig. 3c). We isolated 4 biallelically deleted HUDEP-2 clones. We 160 
found that CHD4 expression decreased by 56-79% after deletion of the upstream elements, 161 
similar to the decrease observed after editing ZNF410 itself. Consistent with reduced expression 162 
of CHD4, 𝛾-globin was induced (Fig. 3f, Supp. Fig 3d, 3e). No change in CHD4 expression was 163 
observed upon ZNF410 editing in the absence of the upstream elements, suggesting that the 164 
control of CHD4 expression requires these elements. We did not observe further 𝛾-globin 165 
induction in CHD4 upstream element deleted cells upon ZNF410 editing (Fig. 3g, Supp. Fig. 166 
3e). In contrast, 𝛾-globin increased in these same cells upon ZBTB7A editing, indicating the 167 
cells were competent for further 𝛾-globin induction. We performed RNA-seq of CHD4 𝛥6.7 kb 168 
element deleted cells after ZNF410 editing (Fig. 3h). In contrast to HUDEP-2 cells, we only 169 
observed 2 differentially expressed genes after ZNF410 editing in CHD4 𝛥6.7 kb element 170 
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deletion cells, consistent with our prior results that nearly all gene expression changes found 171 
after ZNF410 editing are due to changes in CHD4 expression. Together these results suggest 172 
that ZNF410 represses 𝛾-globin exclusively by binding upstream elements and trans-activating 173 
CHD4.  174 
 175 
ZNF410 is a non-essential gene 176 
 177 
ZNF410 and its mouse ortholog Zfp410 share 94% amino acid identity, including 98% at the 178 
cluster of 5 ZnFs12. We performed CUT&RUN to investigate the chromatin occupancy of 179 
endogenous Zfp410 in a mouse erythroid cell line (MEL cells). Similar to results in human 180 
erythroid precursors, we observed that genomic enrichment of Zfp410 binding was highly 181 
restricted to the Chd4 locus, with 77-fold enrichment at the promoter and 45-fold enrichment at 182 
the Chd4 -6 kb enhancer, each overlapping accessible chromatin regions and motif clusters 183 
(Fig. 4a, b). The third most enriched site for Zfp410 occupancy was at the promoter of 184 
Hist1h2bl, with ~14 fold enrichment, although no motifs were observed at this site (Supp. Fig. 185 
4a). To evaluate the requirement of ZNF410 in normal development and homeostasis, we 186 
investigated mice with a loss-of-function allele of the mouse ortholog Zfp410. We obtained 187 
mouse embryonic stem cells that are heterozygous for a Zfp410 gene trap allele (Gt) from the 188 
European Mouse Mutant Cell Repository (EuMMCR). The targeting cassette was inserted to 189 
intron 5 to disrupt expression of full-length Zfp410 (Supp. Fig. 4b). Of note, exons 6-9 encode 190 
the five ZnFs (Supp. Fig. 4c). We derived heterozygous mice with germline transmission of this 191 
allele. Although the sample size is currently small, we observed 6 Zfp410Gt/Gt  homozygotes out 192 
of 20 live births from Zfp410+/Gt heterozygote intercrosses, consistent with expected Mendelian 193 
transmission (Fig. 4c). Zfp410 expression was reduced by >98% in Zfp410Gt/Gt homozygous 194 
mouse whole blood (Fig. 4d). The Zfp410Gt/Gt homozygotes showed moderately reduced body 195 
weight compared to heterozygotes or wt mice (Fig. 4e), but otherwise appeared healthy and 196 
active. Analysis of complete blood counts showed apparently unremarkable hematologic 197 
parameters in Zfp410Gt/Gt homozygous mice, including no evidence of anemia or hemolysis (Fig. 198 
4f). The absence of a severe phenotype of constitutive Zpf410 loss-of-function is notable in 199 
comparison to other HbF regulators. For example, Bcl11a deficient mice experience perinatal 200 
lethality18, Zbtb7a deficient mice mid-gestation embryonic lethality due to anemia11, and Chd4 201 
deficient mice pre-implantation embryonic lethality19. Together these results suggest that 202 
ZNF410 is an evolutionarily conserved HbF repressor that is not essential for vertebrate 203 
survival.    204 
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  205 
ZNF410 appears dispensable for human erythropoiesis and hematopoiesis 206 
 207 
To evaluate the role of ZNF410 in human hematopoiesis, we performed gene editing of ZNF410 208 
in primary human hematopoietic stem and progenitor cells (HSPCs). We electroporated 3xNLS-209 
SpCas9 and sgRNA as ribonucleoprotein (RNP) to CD34+ HSPCs from two healthy donors and 210 
achieved >99% indels (Fig. 5a, b). Since all of these measured indels were +1 insertions, 211 
biallelic ZNF410 knockouts comprised nearly all cells in the population. To test the role of 212 
ZNF410 more broadly in hematopoiesis, we performed xenotransplantation of edited HSPCs to 213 
immunodeficient NBSGW mice (Fig. 5a). NBSGW mice support multilineage (lymphoid, myeloid 214 
and erythroid) human engraftment in absence of conditioning therapy20. After 16 weeks we 215 
analyzed bone marrow from engrafted recipients. We observed similar human hematopoietic 216 
engraftment for ZNF410 edited HSPCs compared to mock control xenografts (Fig. 5c). ZNF410 217 
+1 insertion frameshift indels were observed at >99% frequency in total BM human 218 
hematopoietic cells similar to the input cell product (Fig. 5b). A comparable distribution of 219 
multilineage hematopoietic reconstitution was found in control and ZNF410 edited recipients, 220 
including B-lymphocyte, T-lymphocyte, granulocyte, monocyte, HSPC and erythroid 221 
contributions (Fig. 5d, e). We found that CHD4 expression was decreased by ~60% in human 222 
erythroid cells sorted from bone marrow, similar to in vitro results (Fig. 5f). The level of HbF as 223 
measured by HPLC from engrafting human erythrocytes was ~2.5% in controls and ~17% in 224 
ZNF410 edited recipients (Fig. 5g).  225 
 226 
For comparison, we also performed xenotransplant experiments with BCL11A and ZBTB7A 227 
edited HSPCs. Consistent with the known role of BCL11A in supporting HSC self-renewal (and 228 
unlike the selective erythroid impact of BCL11A erythroid enhancer editing21), we observed 229 
reduced human chimerism in the bone marrow of recipients of BCL11A exon edited HSPCs 230 
after 16 weeks, reduced BCL11A edits compared to input cell product, and reduced fraction of 231 
frameshift alleles compared to total edits (Supp. Fig. 5a, b). For ZBTB7A, the fraction of 232 
engrafting human hematopoietic cells was similar to controls but the gene edits were reduced 233 
compared to input cell product (Supp. Fig. 5a, b). During erythroid maturation culture, ZBTB7A 234 
edited HSPCs showed impaired terminal erythroid maturation potential based on 235 
immunophenotype and enucleation frequency, in contrast to ZNF410 edited cells (Supp. Fig. 236 
5c, d). Together these results suggest HSPCs bearing BCL11A and ZBTB7A loss-of-function 237 
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alleles are under negative selective pressure during hematopoietic repopulation and 238 
erythropoiesis unlike ZNF410 edited cells. 239 
 240 
Discussion 241 
  242 
The advances in knowledge of the molecular details of hemoglobin switching have begun to 243 
bear fruits in the form of novel autologous therapies1. A host of HSC-based therapies that 244 
reduce the expression of BCL11A in erythroid cells or prevent its binding to HBG1/2 promoter 245 
sequences are in clinical trials or late preclinical development. However the clinical unmet need 246 
remains vast, with ~300,000 infants estimated to be born each year worldwide with sickle cell 247 
disease and tens of thousands more with severe 𝛽-thalassemia. The feasibility in terms of cost 248 
and infrastructure to scale up autologous cell-based therapies remains uncertain. Furthermore 249 
the toxicity of myeloablative transplantation will likely render these therapies out of reach to 250 
many patients.  251 
 252 
The most realistic near-term hope to develop scalable therapies to address the root cause of 253 
these diseases would be through pharmacotherapy. Drugs that could interrupt molecular 254 
vulnerabilities required for adult erythroid cells to maintain fetal globins in a silenced state are 255 
greatly needed. These could complement or even supplant existing treatments like 256 
hydroxyurea22. BCL11A itself would certainly represent a preeminent target. Its roles in 257 
erythropoiesis besides HbF silencing are modest. However BCL11A plays essential roles in 258 
various hematopoietic lineages, including in B-lymphocytes, dendritic cells and hematopoietic 259 
stem cells18,23–25. In addition, it has functions beyond hematopoiesis not only in the central 260 
nervous system but also in breast and pancreatic cells26,27. Another exciting target would be 261 
ZBTB7A given its potent role in HbF repression. However ZBTB7A is required for terminal 262 
erythropoiesis and germinal center B cell maturation and plays important roles in T-263 
lymphocytes, osteoclasts and HSCs28. A specific NuRD subcomplex including CHD4, 264 
GATAD2A, MBD2, MTA2 and HDAC2 is required for HbF silencing6,29. Targeting NuRD 265 
including key protein-protein interactions appears promising but would need to navigate the 266 
numerous gene expression programs that depend on this chromatin complex. For most of the 267 
known HbF regulators, their pleiotropic roles could yield potential on-target liabilities with narrow 268 
therapeutic index even if rational targeting approaches could be devised. 269 
 270 
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Here we identify ZNF410 as a novel HbF repressor that acts specifically to enhance the 271 
expression of CHD4. Complete knockout of ZNF410 is well-tolerated, apparently since the 272 
remaining level of CHD4 is sufficient to maintain cellular functions. Zfp410 mutant mice survive 273 
to adulthood and ZNF410 knockout HSPCs demonstrate no defects in erythroid maturation or 274 
hematopoietic reconstitution. Traditionally TFs have been considered undruggable targets. 275 
However the example of small molecules binding and resulting in specific degradation of zinc 276 
finger proteins like IKZF1 has encouraged the development of ligands to modulate DNA-binding 277 
factors30,31.  278 
 279 
ZNF410 appears to represent a special form of gene regulator. Conventional DNA-binding TFs 280 
bind and directly control the expression of thousands of genomic targets. In contrast, ZNF410 281 
shows unique binding to CHD4. This exquisite specificity appears to be achieved through a 282 
remarkable clustering of 27 ZNF410 binding sites at the CHD4 promoter and -6 kb enhancer, a 283 
density unlike anywhere else in the genome. Both ZNF410 itself and its two target elements at 284 
CHD4 are highly conserved across vertebrates. Despite thousands of ZNF410 motifs across the 285 
genome, we detected minimal ZNF410 occupancy at these sites. The absence of detectable 286 
ZNF410 occupancy or chromatin accessibility even at GALNT18 intron 1 with 6 clustered motif 287 
instances suggests that motif clusters may be necessary but insufficient for ZNF410 binding. 288 
Another example of clustered homotypic TF binding sites associated with gene control is the 289 
binding of ZFP64 to the MLL gene promoter, activating the expression of the chromatin 290 
regulator MLL, although in this case ZFP64 shows a limited set of additional direct target 291 
genes32. CHD4 is an especially abundant nuclear protein in erythroid precursors33. 292 
Haploinsufficiency of CHD4 (or MLL) causes impaired intellectual development and congenital 293 
anomalies, suggesting that chromatin regulatory complexes must be maintained at precise 294 
levels to maintain proper gene regulation, particularly during development34–36. There are more 295 
than a thousand putative DNA-binding TFs, for many of which the genomic binding sites and 296 
regulons remain poorly characterized37. ZNF410 may be emblematic of a class of TFs relying on 297 
homotypic motif clusters38 with limited gene targets that are devoted to maintenance of core 298 
cellular programs.   299 
 300 
In summary, here we identify ZNF410 as a dispensable TF that represses HbF level in adult-301 
stage erythroid precursors by devoted maintenance of NuRD subcomplex levels through binding 302 
a singular cluster of sequences upstream of CHD4.  303 
  304 
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Methods 305 
 306 
Cell culture 307 
HUDEP-2 cells39 were cultured as previously described40. Expansion phase medium for 308 
HUDEP-2 cells consists of SFEM (Stemcell Technologies #09650) base medium supplemented 309 
with 50 ng/ml recombinant human SCF (R&D systems #255-SC), 1 µg/ml doxycycline (Sigma 310 
Aldrich #D9891), 0.4 µg/ml dexamethasone (Sigma Aldrich #D4902), 3 IU/ml EPO (Epoetin Alfa, 311 
Epogen, Amgen) and 2% Penicillin-Streptomycin solution (10,000 U/mL stock). Erythroid 312 
differentiation medium (EDM) for HUDEP-2 cells consists of Iscove's Modified Dulbecco's 313 
Medium (IMDM, ThermoFisher #12440053) supplemented with 1% L-Glutamine (Gibco 314 
#25030081), 330 µg/mL human holo-Transferrin (Sigma #T0665), 10 µg/mL human insulin 315 
(Sigma #I9278), 2 IU/mL heparin (Sigma #H3149), 5% inactivated human plasma (Octaplas, 316 
blood group AB, Octapharma), 3 IU/mL EPO (Epoetin Alfa, Epogen, Amgen) and 2% Penicillin-317 
Streptomycin solution (10,000 U/mL stock). EDM-2 medium for HUDEP-2 cells is EDM 318 
supplemented with 100 ng/ml human SCF and 1 µg/ml doxycycline. CD34+ HSPCs from adult 319 
mobilized peripheral blood from de-identified healthy donors were purchased from Fred 320 
Hutchinson Cancer Research Center, Seattle, Washington. Upon thawing, CD34+ HSPCs were 321 
resuspended in X-VIVO 15 medium (Lonza #04-380Q) containing 50 ng/ml recombinant human 322 
Flt-3 ligand (Peprotech #300-19), 100 ng/ml recombinant human TPO (Peprotech #300-18) and 323 
100 ng/ml recombinant human SCF (R&D systems #255-SC) (referred to as X-VIVO complete 324 
medium). Erythroid differentiation was performed in 3 phases as previously described41. Mouse 325 
erythroleukemia cells, MEL-745A cl. DS19, were cultured in RPMI 1640 medium supplemented 326 
with 10% fetal bovine serum and 1% Penicillin-Streptomycin.  327 
 328 
sgRNA library screening 329 
For library screening, HUDEP-2 cells with stable expression of LentiCas9-Blast (Addgene 330 
plasmid 52962) were transduced at a low multiplicity of infection (MOI) with virus containing 331 
sgRNA library cloned in lentiGuide-Puro (Addgene plasmid 52963) to ensure that most cells 332 
received only one sgRNA in expansion phase medium42. The sgRNA library included 18,020 333 
gRNA overlapping those in GeCKOv243 and Avana44 libraries targeting 1591 transcription 334 
factors and 13 genes of the NuRD complex as controls. After 24 hours, cells were transferred to 335 
and cultured in erythroid differentiation medium for 14 days. At the end of erythroid culture, cells 336 
were processed for intra-cellular HbF staining using Fetal Hemoglobin Monoclonal Antibody 337 
(HBF-1) conjugated to FITC (Thermo Fisher #MHFH01), and HbF+ cells were sorted by FACS 338 
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as previously described6. Genomic DNA was extracted from the total cell population and from 339 
HbF+ sorted cells and deep sequenced to identify guide RNAs with enrichment in the HbF+ pool 340 
as previously described6. Briefly, two step PCR was performed to amplify sgRNA cassette from 341 
genomic DNA, using Herculase II Fusion DNA polymerase (Agilent #600677). Multiple reactions 342 
of the first PCR were set up for each sample in order to maximize genomic DNA input up to 343 
1000 cell equivalents per sgRNA. After the first PCR, all reactions for each sample were pooled 344 
and 1 ul of this mix used as input for the second PCR reaction which was performed in 345 
duplicate. Illumina adaptor and sample barcodes added in the second PCR. Primers for the 346 
second PCR were of variable length to increase library complexity42. Sequences of PCR primers 347 
can be found in the Supplementary Table. Amplicons obtained from the second PCR were 348 
purified by gel extraction and quantified using the Qubit dsDNA HS assay kit (Invitrogen 349 
#Q32851). Single-end 75 bp sequencing was performed on the NextSeq 500 platform by the 350 
Molecular Biology Core Facilities at Dana-Farber Cancer Institute. Candidate HbF regulators 351 
were identified by analyzing sequencing data using the model-based analysis of genome-wide 352 
CRISPR-Cas9 Knockout (MAGeCK) computational tool45.  353 
 354 
Validation in HUDEP-2 cells 355 
Candidate HbF regulators identified by the screen were validated in arrayed format in HUDEP-2 356 
cells. HUDEP-2 cells with stable expression of lentiCas9-Blast were transduced with sgRNA 357 
cloned in lentiGuide-Puro in expansion phase medium. 24 hours after transduction, cells were 358 
cultured in EDM2 for 4 days, EDM with doxycycline for 3 days and EDM without doxycycline for 359 
2 days as previously described40. These culture conditions result in differentiation of normal 360 
HUDEP-2 cells to orthochromatic erythroblasts. At the end of erythroid differentiation cells were 361 
divided into aliquots and processed for intra-cellular HbF staining, RNA isolation and 362 
hemoglobin HPLC. In addition to mock treated cells, non-targeting sgRNAs or sgRNAs targeting 363 
either AAVS1 or a functionally neutral locus on chr2 (so-called “safe targeting” sgRNA)46 were 364 
used as experimental controls as indicated in each figure legend. For RNA sequencing 365 
experiments HUDEP-2 cells were cultured in expansion phase medium for 6 days after 366 
transduction or electroporation. RNA was isolated using Trizol according to the manufacturer’s 367 
protocol (Thermo Fisher #15596026). Purified RNA was treated with DNase I. mRNA libraries 368 
were prepared and sequenced by the Molecular Biology Core Facilities at Dana-Farber Cancer 369 
Institute. 370 
 371 
 372 
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Generation of ZNF410 null HUDEP-2 cell clones 373 
The entire coding sequence of ZNF410 was deleted in HUDEP-2 cells using paired Cas9 374 
cleavages. ZNF410 null HUDEP-2 cell clones were generated in two steps. In the first step a 375 
cell clone with heterozygous deletion of ZNF410 was obtained using the gRNAs ZNF410-del-5’-376 
tgt1 and ZNF410-del-3’-tgt1. In the second step this heterozygous ZNF410 null clone was 377 
retargeted using a second pair of guide RNAs, ZNF410-del-5’-tgt2 and ZNF410-del-3’-tgt2, to 378 
obtain biallelic deletion of ZNF410. Three individual ZNF410 null clones were obtained by 379 
limiting dilution of bulk edited cells. Mono- or biallelic deletion clones were identified by PCR 380 
amplification of the genomic DNA flanking the deletion (outer PCR) and inside the targeted 381 
region (inner PCR) using the following primers: ZNF410-outer-FP/RP and ZNF410-inner-FP/RP. 382 
For the rescue experiment, the three ZNF410 null clones were transduced with either an HA-383 
tagged ZNF410 construct or an HA-tagged nuclear localization sequence (NLS) containing 384 
control vector. Successfully transduced cells were obtained by selection of cells using blasticidin 385 
(Invivogen #ant-bl-05). 386 
 387 
Validation in CD34+ HSPCs 388 
CD34+ cells were thawed and maintained in X-VIVO complete medium for 24 hours. 100,000 389 
cells per condition were electroporated using the Lonza 4D nucleofector with 100 pmols 3xNLS-390 
Cas9 protein and 300 pmols modified sgRNA targeting the gene of interest. In addition to mock 391 
treated cells, AAVS1 targeting or “safe-targeting” RNPs were used as experimental controls as 392 
indicated in each figure legend. After electroporation cells were differentiated to erythroblasts as 393 
described previously41. 4 days after electroporation, genomic DNA was isolated from an aliquot 394 
of cells, the sgRNA targeted locus was amplified by PCR and processed for Sanger 395 
sequencing. Sequencing results were analyzed by Synthego’s ICE algorithm to obtain editing 396 
efficiency and allele contributions. At the end of erythroid culture (day 18) cells were processed 397 
for surface marker / enucleation analysis by staining with anti-CD71 (PE-Cy7 conjugated, 398 
eBioscience #25-0719-42), anti-CD235a (APC conjugated, eBioscience #17-9987-42) and 399 
Hoechst 33342 (Invitrogen #H3570) following manufacturer’s recommendations for antibody 400 
concentration and flow cytometry data acquisition on the BD LSR Fortessa. Cells were also 401 
processed for hemoglobin HPLC using the Bio-Rad D-10 hemoglobin testing system.   402 
 403 
Dense mutagenesis of ZNF410 404 
180 guide RNAs were identified by searching for 20-mer sequences upstream of an NGG PAM 405 
on the sense and antisense strands of the consensus coding sequence (CCDS) for ZNF410 406 
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obtained from the Ensembl genome browser (Transcript ID ENST00000555044.6). Lentiviral 407 
sgRNA libraries were synthesized as previously described47 and pooled screening was 408 
performed as described in the sgRNA library screening section above. Sequencing results were 409 
analyzed by the CRISPRO tool48. For each gRNA an HbF enrichment score was calculated 410 
comparing the abundance of the gRNA in HbF-high cells to the total cell pool at the end of 411 
erythroid culture. Cell fitness scores were calculated by comparing the abundance of the gRNA 412 
in cells at the end of erythroid culture to the starting library. The CRISPRO algorithm maps the 413 
cell fitness and HbF enrichment score to gene, transcript and protein coordinates and lists 414 
associated protein structural domains.  415 
  416 
CUT&RUN 417 
CUT&RUN was performed to identify the genome wide ZNF410 / Zfp410 DNA binding profile as 418 
previously described13. The antibodies used were anti-HA antibody (ThermoFisher #71-5500) in 419 
HUDEP-2 cells expressing an HA-tagged ZNF410 construct or anti-ZNF410 (Abcam 420 
#ab174204) to detect endogenously expressed ZNF410 in HUDEP-2 and primary human 421 
CD34+ cells as well as endogenously expressed Zfp410 in MEL cells. Normal rabbit IgG 422 
polyclonal antibody (Millipore Sigma #12370) was used as a control for non-specific sequence 423 
enrichment.  Anti-H3K27me3 antibody (Cell signaling Technology #9733) was used as a 424 
positive control for the steps leading up to the chromatin release. Protein A-MNase was kindly 425 
provided by Dr. Steve Henikoff. Sequencing libraries were prepared using the NEBNext Ultra™ 426 
II DNA Library Prep Kit for Illumina as previously described9. Paired-end 42bp sequencing was 427 
performed on the NextSeq 500 platform by the Molecular Biology Core Facilities at Dana-Farber 428 
Cancer Institute. Sequencing data analyses was adapted from previous protocols9,13. FastQC 429 
(Babraham Institute) was performed for all samples to check sequencing quality. Adapter 430 
sequences were trimmed with Trimmomatic49 with the following settings:  431 
“ILLUMINACLIP:$TRIMMOMATIC/adapters/TruSeq3-PE.fa:2:15:4:4:true 432 
SLIDINGWINDOW:4:15 MINLEN:25.” Trimmed reads were aligned to the human reference 433 
genome hg19 using bowtie250 with the following settings: “--end-to-end --no-unal --no-mixed --434 
no-discordant --dovetail --phred33 -p 4.” The resulting alignment files (.sam) were converted to 435 
sorted, indexed bam files and marked for duplicates using Picard 436 
(https://broadinstitute.github.io/picard/). Reads were filtered using an alignment score cutoff of 437 
10 with samtools51. Peak calling was performed using macs252 with the following settings: 438 
“callpeak -f BAMPE -t [ test replicates] -c [control replicates] -B -g [hs or mm] -q 0.05 -n 439 
[outputID].” Genomic regions annotated as part of the ENCODE project blacklist53 as 440 
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problematic regions for alignment of high-throughput functional genomics data were excluded 441 
from analysis using files ENCFF001TDO (hg19, Birney lab, EBI) and ENCFF547MET (mm10, 442 
Kundaje lab, Stanford) and BEDtools54. Locus footprinting was performed to identify regions of 443 
DNA that are relatively protected from MNase cleavage compared to neighboring regions due to 444 
occupancy by a transcription factor. Footprint patterns at a locus were determined by 445 
enumerating the ends of each fragment sequenced and aligned to the locus. Data was 446 
visualized using IGV55.  447 
 448 
Genome-wide motif mapping 449 
Genome-wide ZNF410 DNA binding motif instances were mapped using the pwmscan webtool 450 
(https://ccg.epfl.ch/pwmtools/pwmscan.php) and the ZNF410 motif MA0752.1 from the JASPAR 451 
CORE 2018 vertebrates motif library. The number of motif instances in the genome was 452 
enumerated using a 3 kb sliding window with a 100 bp overlap to determine genomic distribution 453 
of motif occurrence for ZNF410. Motifs that fall within the overlapping region between genomic 454 
windows are assigned to the adjacent window with the greater number of motifs, or if both 455 
adjacent windows have the same number of motifs, motifs are assigned to the first of the two 456 
windows.  457 
 458 
ATAC-seq and DNase-seq identification of regions of open chromatin  459 
ATAC-seq was performed in HUDEP-2 cells grown in expansion phase medium following the 460 
OMNI-ATAC protocol56. MEL DNase-seq data was obtained from the ENCODE project57,58 461 
(https://www.encodeproject.org/) from the lab of John Stamatoyannopoulos, UW (dataset: 462 
ENCSR000CNN, file: ENCFF990ATO).  463 
 464 
DNA sequence conservation 465 
SiPhy rate59 (10 mer) from: http://www.broadinstitute.org/igvdata/hg19/omega.10mers.wig.tdf. 466 
 467 
GSEA 468 
Genes that were differentially expressed in ZNF410 targeted HUDEP-2 cells compared to 469 
AAVS1 targeted control cells were compared by gene set enrichment analysis (GSEA)60,61 to 470 
genes that were differentially expressed in CHD4 targeted HUDEP-2 cells compared to non-471 
targeting control cells6. The list of genes differentially expressed in CHD4 targeted HUDEP-2 472 
cells are genes that were differentially expressed in both datasets (q<0.05) when either the 473 
helicase domain or the CHDCT2 domain of CHD4 were perturbed using sgRNA 474 
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GGTGTCAGTGCCCTGAGCCC or GAATTCGGGCAATGGTAGCT respectively from previously 475 
published data6. The motivation for combining these two datasets is based on the observation 476 
that helicase domain targeting is toxic to cells while CHDCT2 domain targeting is better 477 
tolerated and so the combined list of differentially expressed genes better represents gene 478 
expression changes due to CHD4 ablation than either dataset alone.  479 
 480 
Gene dependency correlation 481 
Gene dependency scores for 558 cell lines were obtained from the Achilles Avana 20Q2 Public 482 
CERES dataset of the Depmap portal (DepMap, Broad (2020): DepMap 20Q2 Public. figshare. 483 
Dataset. https://doi.org/10.6084/m9.figshare.12280541.v4. )16,17. Project Achilles performs 484 
genome scale CRISPR/Cas9 loss of function screening in cancer cell lines and uses CERES to 485 
determine a dependency score for each gene in each cell line. Pearson’s correlations of 486 
dependency scores and p-values were calculated for ZNF410 and every other gene in the 487 
dataset.  488 
 489 
Analysis of gene expression across human tissues 490 
ZNF410 and CHD4 expression values (TPM) across 54 human tissues were obtained from the 491 
GTEx Portal15 on 10/01/2019. Pearson correlation was used to compare the expression of 492 
ZNF410 and CHD4.  493 
 494 
Generation of CHD4 Δ6.7 kb and Δ6.9 kb clones 495 
The genomic region upstream of CHD4 encompassing the two clusters of ZNF410 DNA binding 496 
motifs was targeted using a pair of sgRNAs (CHD4-proximal-gRNA-1: 497 
GUGCGGUGGGAUUUCCCGGC and  CHD4-distal-gRNA-1: CGAGGCUGUGUCAGCGCCGC 498 
or CHD4-distal-gRNA-2: UUGGUCUGUGGGAUGGACAU) to generate HUDEP-2 clones with 499 
biallelic deletion of the intervening sequence. These clones are termed CHD4 Δ 6.7 kb (for 500 
clones generated using CHD4-proximal-gRNA-1 and CHD4-distal-gRNA-1) or CHD4 Δ6.9 kb 501 
(for clones generated using CHD4-proximal-gRNA-1 and CHD4-distal-gRNA-2). The bulk 502 
population of targeted cells was serial diluted and ~30 cells per plate were plated in 96 well 503 
plates to obtain single cell clones. Mono- or biallelic deletion was identified by PCR amplification 504 
of the genomic DNA flanking the deletion (outer PCR) and inside the targeted region (inner 505 
PCR) using the following primers: CHD4-Outer-FP and CHD4-Outer-RP1 or CHD4-Outer-RP2,  506 
CHD4-Inner-FP and CHD4-Inner-RP (sequences listed in Supplementary Table).  507 
 508 
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RT-qPCR 509 
RNA was isolated using either Trizol (Invitrogen #15596026) or the RNeasy Plus Mini kit 510 
(Qiagen #74136) following the manufacturer’s protocol. RNA was quantified using the Nanodrop 511 
spectrophotometer. cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad 512 
#1708891) following the manufacturer’s recommendations. qPCR was performed using the Sybr 513 
Select Master Mix (Thermo Fisher #4472908) on an Applied Biosystems 7300 or Quant Studio 3 514 
real-time PCR system. Primers used for RT-qPCR are listed in the Supplementary Table. CAT 515 
was used as a reference gene for human cells and Gapdh for mouse cells.  516 
 517 
Generation of Zfp410 gene-trap allele mice 518 
All animal experiments were approved by the Boston Children’s Hospital Institutional Animal 519 
Care and Use Committee. Zfp410 gene-trap allele mice were generated as described below. 520 
C57BL/6 mice were obtained from Charles River Laboratories (Strain Code 027). Mouse ES 521 
cells heterozygous for a Zfp410 gene-trap allele produced in the EUCOMM (European 522 
Conditional Mouse Mutagenesis Program) were purchased from the European Mouse Mutant 523 
Cell Repository (EuMMCR, Germany). The ES cells were derived from a C57BL/6N 524 
background. The targeting cassette was inserted in intron 5 and contains a splice acceptor site 525 
upstream of the lacZ gene that disrupts normal splicing and thus expression of Zfp410 526 
(Supplementary Fig. 4b). This allele also has conditional potential with LoxP sites flanking 527 
exon 6. We purchased 3 ES cell clones (E06, F06 and F07). Karyotype analysis was performed 528 
by EuMMCR. The percentage of cells with normal chromosome count (2n=40) for each clone 529 
was 77% for E06, 70% for F06 and 90% for F07. Clones E06 and F07 were chosen for 530 
blastocyst micro-injections. Chimeric mice were generated by the NIH/NIDDK Center of 531 
Excellence in Molecular Hematology, Mouse Embryonic Stem Cell (ESC) and Gene Targeting 532 
Core facility. C57BL/6 mice were used as the host for blastocyst micro-injections. For clone 533 
E06, there were a total of 13 pups born from 3 pregnant fosters, of which there were 2 male and 534 
1 female chimeric mice. For clone F07, there were 3 pups born from 2 pregnant fosters, none of 535 
which were chimeras. Of the 3 chimeric mice obtained, one male produced germline 536 
transmission of the Zfp410 gene-trap (Gt) allele upon breeding with wildtype C57BL/6 mice. 537 
Mice heterozygous for the Zfp410 gene-trap allele (Zfp410 +/Gt) were intercrossed to generate 538 
mice homozygous for the Zf410 gene-trap allele (Zfp410 Gt/Gt). Mice carrying the Zfp410 gene-539 
trap allele were genotyped using primers flanking the LoxP site in intron 6 (LoxP-FP and LoxP-540 
RP). During homologous recombination, the targeting cassette replaces endogenous DNA 541 
stretches resulting in a slightly different PCR product from the targeted compared to the wildtype 542 
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allele. Peripheral blood was collected from mice at 3 months of age. CBCs were performed on 543 
the Advia hematology system at the BCH-HSCI Flow Core. Values for the normal range of 544 
various hematological parameters for C57BL/6 mice were obtained from the Charles River 545 
Laboratories website (https://animalab.eu/sites/all/pliki/produkty-546 
dopobrania/Biochemistry_and_Hematology_for_C57BL6NCrl_Mouse_Colonies_in_North_Ameri547 
can_for_January_2008_December_2012.pdf). RNA was isolated from whole blood using Trizol 548 
following the manufacturer’s protocol.  549 
 550 
Xenotransplant  551 
NOD.Cg-KitW−41J Tyr + Prkdcscid Il2rgtm1Wjl (NBSGW) mice were obtained from Jackson 552 
Laboratory (Stock 026622). CD34+ HSPCs from adult mobilized peripheral blood from de-553 
identified healthy donors were thawed and recovered in X-VIVO complete medium for 24 hours. 554 
After recovery, cells were electroporated using the Lonza 4D nucleofector with 3xNLS-Cas9 555 
protein and sgRNA. Cells were allowed to recover from electroporation for 24-48 hours in X-556 
VIVO complete medium. Cells were counted and divided equally among 3 or 4 recipient mice 557 
per condition. A portion of cells was subjected to in vitro erythroid differentiation. Pre-transplant 558 
editing efficiency was assessed on day 4 of in vitro culture. In each experiment 4 mice received 559 
cells that were not subjected to electroporation (mock) as experimental controls.  Cells were 560 
resuspended in 200 ul DPBS per mouse and infused by retro-orbital injection into non-irradiated 561 
NBSGW female mice. 16 weeks post transplantation, mice were euthanized, bone marrow was 562 
collected and xenograft analysis was performed as previously described21. Analysis of bone 563 
marrow subpopulations was performed by flow cytometry. Bone marrow cells were first 564 
incubated for 15 minutes with Human TruStain FcX (BioLegend #422302) and TruStain FcX 565 
(anti-mouse CD16/32, BioLegend #101320) to block non-specific binding of immunoglobulin to 566 
Fc receptors, followed by incubation with anti-human CD45 (V450, clone HI30, BD Biosciences 567 
#560367), anti-mouse CD45 (PE-eFluor 610, clone 30-F11, Thermo Fisher #61-0451-82), anti-568 
human CD235a (FITC, BioLegend #349104), anti-human CD33 (PE, BioLegend #366608), anti-569 
human CD19 (APC, BioLegend #302212), anti-human CD3 (PE/Cy7, BioLegend #300420) and 570 
anti-human CD34 (FITC, BioLegend #343504) antibodies. Fixable Viability Dye (eFluor 780, 571 
Thermo Fisher #65-0865-14) was used to exclude dead cells. The percentage of human 572 
engraftment was calculated as hCD45+ cells/(hCD45+ cells + mCD45+ cells) x 100. B-573 
lymphocyte (CD19+), granulocyte (CD33-dim SSC-high) and monocyte (CD33-bright SSC-low) 574 
lineages were gated on the hCD45+ population. HSPCs (CD34+) and T-lymphocyte (CD3+) 575 
lineages were gated on the hCD45+ hCD19- hCD33- population. Human erythroid cells 576 
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(CD235a+) were gated on the hCD45- mCD45- population. The detailed gating strategy is 577 
shown in Supplementary Fig. 6.  578 
 579 
Statistical analyses 580 
All values indicated for replicates (n=x) are biological replicates. p-values were calculated by 581 
two-tailed Student’s t-test. 582 
 583 
Data availability 584 
The datasets generated during the current study are available from the indicated repositories 585 
where applicable or are included in this article. 586 
 587 
Code availability  588 
The scripts used for analysis of CUT&RUN experiments and motif mapping have been provided 589 
in Supplementary Methods.  590 
 591 
Supplementary Methods 592 
  593 
CUT&RUN 594 
Sequencing data obtained from CUT&RUN experiments were analyzed using the following 595 
scripts. The workflow was largely adapted from previous protocols9,13, with the addition of data 596 
filtering based on findings of the ENCODE project53,57. 597 
  598 
The prerequisite Software used in our methods are listed below: 599 
FastQC 0.11.3 600 
Trimmomatic 0.36 601 
Bowtie 2 2.2.9 602 
Samtools 1.3.1 603 
Picard 2.8.0 604 
Bedtools 2.27.1 605 
Deeptools 3.0.2 606 
Macs2 2.1.1.20160309 607 
  608 
1. FastQC (Babraham Institute, version 0.11.3) was performed for all samples to check 609 
sequencing quality. 610 
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$zcat *.fastq.gz 611 
$fastqc Sample1_Read1.fastq 612 
$fastqc Sample1_Read2.fastq 613 
  614 
2. Adapter sequences were trimmed with Trimmomatic49. 615 
$java -jar trimmomatic-0.36.jar PE -threads 4 -trimlog trim.log -phred33 616 
Sample1_Read1.fastq.gz Sample1_Read2.fastq.gz -baseout path-for-617 
output/Sample1_trimmed.fq.gz ILLUMINACLIP:/adapters/TruSeq3-PE.fa:2:15:4:4:true 618 
SLIDINGWINDOW:4:15 MINLEN:25 619 
  620 
3. Trimmed reads were aligned to either the human reference genome hg19 or the mouse 621 
reference genome mm10 using bowtie250. Pre-built bowtie2 index files are available at 622 
http://bowtie-bio.sourceforge.net/tutorial.shtml.  623 
$BOWTIE2_IDX=bowtie2_indexes/hg19 (or bowtie2_indexes/mm10) 624 
$bowtie2 --end-to-end --no-unal --no-mixed --no-discordant --dovetail --phred33 -p 4  -x 625 
${BOWTIE2_IDX} -1 Sample1_trimmed_1P.fq.gz -2 Sample1_trimmed_2P.fq.gz -S 626 
Sample1.sam 627 
  628 
4. The resulting alignment files (.sam) were converted to sorted, indexed bam files and marked 629 
for duplicates using Picard (https://broadinstitute.github.io/picard/). 630 
$java -jar picard-2.8.0.jar SortSam I=Sample1.sam O= Sample1.sorted.bam 631 
SORT_ORDER=coordinate CREATE_INDEX=true 632 
$java -jar picard-2.8.0.jar MarkDuplicates I=Sample1.sorted.bam O=Sample1.dedup.sorted.bam 633 
M=Sample1.dedup.txt REMOVE_DUPLICATES=true 634 
$bedtools bamtobed -i $sampleID.dedup.sorted.bam > $sampleID.dedup.sorted.bed 635 
$cat Sample1.dedup.sorted.bed | awk -v OFS='\t' '{len = $3 - $2; print $0, len }' > 636 
Sample1.dedup.sorted.final.bed 637 
  638 
5. Deduplicated and sorted bam files were converted to bigwig files for visualization in IGV. 639 
These are the files used to generate the representative IgG or ZNF410 data tracks.   640 
$samtools index Sample1.dedup.sorted.bam 641 
$bamCoverage --bam Sample1.dedup.sorted.bam -o Sample1.dedup.sorted.bw --binSize 10 642 
  643 
6. Reads were filtered using an alignment score cutoff of 10 with samtools51. 644 
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$samtools view -b -q 10 Sample_1.dedup.sorted.bam > Sample_1.dedup.filtered.bam 645 
  646 
7. Peak calling was performed using macs252. Biological replicates for test and control samples 647 
were grouped together at this stage. 648 
$sampleID=Sample 649 
$controlID=Control 650 
$outputID=Sample_vs_Control 651 
$macs2 callpeak -f BAMPE -t ${sampleID}_Replicate-1.dedup.filtered.bam 652 
${sampleID}_Replicate-2.dedup.filtered.bam ${sampleID}_Replicate-3.dedup.filtered.bam \ 653 
-c ${controlID}_Replicate-1.dedup.filtered.bam ${controlID}_Replicate-2.dedup.filtered.bam 654 
${controlID}_Replicate-3.dedup.filtered.bam \ -B -g hs -q 0.05 -n ${outputID} 655 
 656 
8. Genomic regions annotated as part of the ENCODE project blacklist53,57 as problematic 657 
regions for alignment of high-throughput functional genomics data were excluded from analysis 658 
using files ENCFF001TDO (hg19, Birney lab, EBI) and ENCFF547MET (mm10, Kundaje lab, 659 
Stanford) and BEDtools54. 660 
$bedtools intersect -a Test_vs_control_peaks.bed -b blacklist.bed -v > 661 
Test_vs_control_blacklist-filtered.bed 662 
 663 
 664 
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Figure Legends 684 
 685 
Figure 1. ZNF410 is a novel HbF repressor. (a) Schematic of CRISPR/Cas9-based knockout 686 
screen in HUDEP-2 cells to identify novel repressors of HbF expression. (b) HbF enrichment 687 
and cell fitness scores for each of 1591 transcription factors and 13 genes of the NuRD 688 
complex. The gene ZNF410 was prioritized for further study based on positive HbF enrichment 689 
score, neutral cell fitness score and unknown role in erythropoiesis and globin regulation. (c) 690 
HUDEP-2/Cas9 cells nontransduced (mock) or transduced with nontargeting (NT) or ZNF410 691 
targeting sgRNA assayed on day 9 of erythroid differentiation with intra-cellular staining (HbF+ 692 
cells), RT-qPCR (HBG1/2 expression, fold change relative to mock) and HPLC (HbF level). Bars 693 
indicate mean values and error bars standard deviation (n=3), with p<0.05 for each comparison 694 
of NT to ZNF410 edited. (d) Intra-cellular HbF staining of HUDEP-2 wild-type (wt) cells and 695 
three ZNF410 knockout HUDEP-2 clones without or with (gray bars) re-expression of ZNF410. 696 
(e) ZNF410 targeted by RNP electroporation of Cas9 and sgRNA in CD34+ HSPCs and 697 
subsequently differentiated to erythroid cells in vitro. Bars indicate median value, experiments 698 
performed in 4 individual donors including biological triplicate for donor 4 (total n=6 replicates). 699 
At the end of erythroid culture (day 18), erythroid maturation was assessed by surface 700 
expression of CD71 and CD235a and enucleation frequency by Hoechst staining. 701 
Representative FACS plots are shown. Quadrant values indicated are mean ± SD; t-test 702 
comparing ZNF410 edited to mock for CD71+CD235a+ and CD71-CD235a+ quadrants did not 703 
show significant differences (p>0.05). HbF level measured by HPLC was increased in ZNF410 704 
edited primary erythroid cells compared to mock control cells (p<0.0001).  705 
  706 
Figure 2. ZNF410 genomic chromatin occupancy is restricted to two CHD4 elements with 707 
densely clustered motifs. (a) Dense mutagenesis of ZNF410 coding sequence by pooled 708 
screening of 180 sgRNAs (NGG PAM restricted). Each circle represents enrichment score of an 709 
individual sgRNA, black line Loess regression. The 5 C2H2 zinc-finger domains (red rectangles) 710 
of ZNF410 appear essential for HbF repression. (b) Genome-wide ZNF410 chromatin 711 
occupancy identified by CUT&RUN in HUDEP-2 samples with ZNF410-HA over-expression 712 
using anti-HA antibody compared to IgG control (n=4 for each). The two peaks with greatest 713 
enrichment of ZNF410 binding were at the CHD4 promoter and CHD4 -6 kb enhancer. The next 714 
most enriched peaks, at CHD4 intron 2 and TIMELESS intron 1, showed substantially less 715 
enrichment. (c) Genome-wide ZNF410 motif occurrences (identified from JASPAR and mapped 716 
by pwmscan) across 3 kb sliding windows. Only three windows comprised more than two 717 
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ZNF410 motifs, including the CHD4 promoter (16 motifs), CHD4 -6 kb enhancer (11 motifs), and 718 
GALNT18 intron 1 (6 motifs). (d) CHD4 locus at 100 kb (top panel) or 1.9 kb resolution (bottom 719 
panels) indicating ZNF410 binding (red peaks) at the CHD4 promoter and CHD4 -6 kb enhancer 720 
regions in representative control IgG (n=9) and anti-HA (n=7) samples in HUDEP-2 cells over-721 
expressing HA-tagged ZNF410, control IgG (n=1) and anti-ZNF410 (n=1) in HUDEP-2 cells, and 722 
control IgG (n=2) and anti-ZNF410 (n=2) in CD34+ HSPC derived erythroid precursors. 723 
Positions of ZNF410 motifs (red rectangles), cleavage frequency (footprint) from ZNF410-HA 724 
CUT&RUN (red bars), accessible chromatin by ATAC-seq (gray peaks, n=3) and DNA 725 
sequence conservation by SiPhy rate.  726 
 727 
Figure 3. ZNF410 represses HbF by activating CHD4. (a) RNA-seq differential gene 728 
expression analysis of ZNF410 (n=3) compared to AAVS1 (n=3) targeted HUDEP-2 cells. 729 
Downregulated and upregulated genes defined by padj<0.01 and L2FC<-1 or >1 respectively. (b) 730 
Comparison of genes upregulated in ZNF410 and CHD4 mutant cells by GSEA shows 731 
enrichment of CHD4 regulated genes in the ZNF410 regulated gene set. (c) Pearson correlation 732 
between ZNF410 dependency and CHD4 dependency across 558 cell lines identifies CHD4 as 733 
the most ZNF410 codependent gene. (d) CHD4 expression measured by RT-qPCR in ZNF410 734 
targeted (n=3) compared to mock and AAVS1 targeted control HUDEP-2 cells (left panel) and in 735 
ZNF410 targeted primary erythroblasts derived from CD34+ HSPCs (n=3, p<0.01) compared to 736 
safe sgRNA targeted control cells on day 7 and day 10 of erythroid culture (right panel). (e) 737 
Cas9 paired cleavages with CHD4-proximal-gRNA-1 and CHD4-distal-gRNA-1 were used to 738 
generate an element deletion clone (CHD4 Δ 6.7 kb), with the biallelic deletion spanning both of 739 
the ZNF410 binding regions upstream of CHD4. (f) CHD4 expression measured by RT-qPCR in 740 
the CHD4 Δ 6.7 kb clone compared to 3 individual HUDEP-2 cell clones plated in parallel. HBG 741 
expression relative to total β-like globin (HBG+HBB) measured by RT-qPCR in the CHD4 Δ 6.7 742 
kb deletion clone compared to control clones. (g) CHD4 Δ 6.7 kb clones and HUDEP-2 cells 743 
were subjected to control (safe) and ZNF410 targeting by RNP electroporation. Relative CHD4 744 
and HBG expression measured by RT-qPCR. (h) RNA-seq differential gene expression analysis 745 
of ZNF410 targeted (n=3) compared to AAVS1 targeted (n=3) CHD4 Δ 6.7 kb clones. 746 
Downregulated and upregulated genes defined by padj<0.01 and L2FC<-1 or >1 respectively.  747 
  748 
Figure 4. Zfp410 deficient mice are viable with unremarkable hematology. (a) CUT&RUN in 749 
mouse erythroleukemia (MEL) cells using anti-Zfp410 antibody (n=3) and IgG control (n=3). 750 
Enrichment for Zfp410 binding concentrated at Chd4 promoter (~77 fold enrichment) and Chd4 -751 
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6 kb enhancer (~45 fold enrichment) peaks. The next most enriched peak was at the Hist1h2bl 752 
promoter (~14 fold enrichment). (b) Chd4 locus showing Zfp410 binding (red peaks) at the Chd4 753 
promoter and Chd4 -6 kb enhancer in representative IgG control (n=3) and anti-Zfp410 (n=3) 754 
samples. Positions of Zfp410 motifs (red rectangles) and accessible chromatin by DNase-seq 755 
(gray peaks). (c) Mouse ES cells heterozygous for Zfp410 gene-trap allele (Gt), obtained from 756 
EuMMCR, were used to generate heterozygous (Zfp410 +/Gt) and homozygous (Zfp410 Gt/Gt) 757 
gene-trap mice, with Zfp410 +/Gt intercrosses yielding 20 progeny from 4 litters. (d) Zfp410 758 
expression, measured by RT-qPCR using primers spanning exons 5 and 6, was diminished in 759 
Zfp410 Gt/Gt (n=3) mouse peripheral blood compared to heterozygous (n=7, p<0.05) and 760 
wildtype control animals. (e) Mouse weight was measured at indicated time points over the 761 
course of 15 weeks. (f) Peripheral blood hematological parameters, with normal ranges for 762 
hemoglobin, mean corpuscular volume (MCV), reticulocyte, white blood cell (WBC), neutrophil 763 
and platelet count shown by dotted lines. 764 
 765 
Figure 5. ZNF410 deficient human HSPCs de-repress HbF and retain repopulation 766 
potential. (a) Schematic of gene editing and transplant of human CD34+ HSPCs in 767 
immunodeficient NBSGW mice. Animals were euthanized 16 weeks post-transplant and bone 768 
marrow (BM) was harvested and sorted into various subpopulations by flow cytometry. (b-e) 769 
Two independent CD34+ HSPC donors were edited and transplanted into 6 mice for each 770 
condition (mock or ZNF410 edited). Each symbol represents one mouse, recipients of donor 1 771 
depicted as circles and donor 2 as triangles. Bars indicate median value. (b) Indel frequency at 772 
ZNF410 was quantified in input cells 4 days after electroporation and in total and sorted 773 
engrafted BM cells. Percentage of frameshift alleles is represented in gray and the percentage 774 
of in-frame alleles is represented in white for each bar. (c) Engraftment of human hematopoietic 775 
cells assessed by hCD45+ compared to total CD45+ cells. (d) B-lymphocytes (CD19+), 776 
granulocytes (CD33-dim SSC-high) and monocytes (CD33-bright SSC-low) expressed as 777 
fraction of hCD45+ cells. HSPCs (CD34+) and T-lymphocytes (CD3+) expressed as fraction of 778 
hCD45+ CD19- CD33- cells. (e) Erythroid cells (hCD235a+) expressed as fraction of hCD45- 779 
mCD45- cells. (f) CHD4 expression measured by RT-qPCR in human erythroid cells from 780 
control (n=4) and ZNF410 edited (n=4) xenografts. (g) HbF measured by HPLC from 781 
hemolysates of sorted BM hCD235a+ cells. 782 
 783 
 784 
 785 
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Supplementary Figure Legends 786 
 787 
Supplementary Figure 1. Absent ZNF410 chromatin occupancy. (a-c) ɑ-like and 𝛽-like 788 
globin gene clusters and GALNT18 intron 1 with a cluster of 6 ZNF410 motifs indicating 789 
absence of ZNF410 occupancy in representative CUT&RUN control IgG (n=9) and anti-HA 790 
(n=7) in HUDEP-2 cells over-expressing HA-tagged ZNF410, control IgG (n=1) and anti-791 
ZNF410 (n=1) in HUDEP-2 cells, and control IgG (n=2) and anti-ZNF410 (n=2) in CD34+ HSPC 792 
derived erythroid precursors. Positions of ZNF410 motifs (red rectangles), accessible chromatin 793 
by representative ATAC-seq in HUDEP-2 cells (gray peaks, n=3) and DNA sequence 794 
conservation by SiPhy rate.  795 
 796 
Supplementary Figure 2. ZNF410 chromatin occupancy. (a) The third most enriched peak 797 
for ZNF410 binding (following CHD4 promoter and -6 kb enhancer) by CUT&RUN with anti-HA 798 
antibody in HUDEP-2 cells over-expressing ZNF410-HA was at TIMELESS intron 1. 799 
Representative CUT&RUN control IgG (n=9) and anti-HA (n=7) in HUDEP-2 cells over-800 
expressing HA-tagged ZNF410, control IgG (n=1) and anti-ZNF410 (n=1) in HUDEP-2 cells, and 801 
control IgG (n=2) and anti-ZNF410 (n=2) in CD34+ HSPC derived erythroid precursors. 802 
Positions of ZNF410 motifs (red rectangles), accessible chromatin by representative ATAC-seq 803 
in HUDEP-2 cells (gray peaks, n=3), DNA sequence conservation by SiPhy rate, and repetitive 804 
elements from RepeatMasker. (b) A total of 5 peaks were identified by CUT&RUN with anti-805 
ZNF410 antibody in HUDEP-2 cells. The top 4 peaks were at the CHD4 promoter or -6 kb 806 
enhancer, the fifth was at DPY19L3 intron 5. (c) A total of 5 peaks were identified by CUT&RUN 807 
with anti-ZNF410 antibody in CD34+ HSPC derived erythroid precursors. All 5 peaks were at 808 
the CHD4 promoter or -6 kb enhancer. (d) Peak of ZNF410 occupancy at DPY19L3 intron 5 in 809 
HUDEP-2 cells.  810 
 811 
Supplementary Figure 3. ZNF410 represses HbF by activating CHD4. (a) Comparison of 812 
genes downregulated in ZNF410 and CHD4 mutant cells by GSEA shows enrichment of CHD4 813 
regulated genes in the ZNF410 regulated gene set. (b) Correlation of ZNF410 and CHD4 814 
expression across 54 human tissues from GTEx (Pearson r=0.77, p<0.0001). (c) Cas9 paired 815 
cleavages with CHD4-proximal-gRNA-1 and CHD4-distal-gRNA-1 (CHD4 Δ 6.7 kb) or CHD4-816 
proximal-gRNA-1 and CHD4-distal-gRNA-2 (CHD4 Δ 6.9 kb) were used to generate HUDEP-2 817 
clones with biallelic deletions spanning both of the ZNF410 binding regions upstream of CHD4. 818 
Positions of ZNF410 motifs (red rectangles) and accessible chromatin by ATAC-seq (gray 819 
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peaks) shown. (d) CHD4 expression measured by RT-qPCR in CHD4 Δ 6.9 kb clones 820 
compared to HUDEP-2 cells. (e) CHD4 Δ 6.9 kb clones and HUDEP-2 cells were subjected to 821 
AAVS1 (negative control), ZNF410 and ZBTB7A targeting using RNP electroporation of 3X-822 
NLS-Cas9 and sgRNA. Left panel, editing efficiency measured by indel frequency in HUDEP-2 823 
cells and CHD4 Δ 6.9 kb clones targeted with ZNF410 or ZBTB7A sgRNAs. The shaded portion 824 
of the bar represents the percentage of indels resulting in frameshift (fs) alleles. The white 825 
portion of the bar represents in-frame indels. Right panel, HBG expression relative to total β-like 826 
globin (HBG+HBB) was measured by RT-qPCR in HUDEP-2 cells and CHD4 Δ 6.9 kb clones 827 
targeted with AAVS1 (negative control), ZNF410 or ZBTB7A sgRNAs. 828 
 829 
Supplementary Figure 4. Zfp410 is the conserved mouse ortholog of ZNF410. (a) 830 
CUT&RUN performed in mouse erythroleukemia (MEL) cells using anti-Zfp410 antibody (n=3) 831 
and IgG control (n=3). The third most enriched Zfp410 peak (following Chd4 promoter and Chd4 832 
-6 kb enhancer) was at the Hist1h2bl promoter. No Zfp410 motifs were identified at this locus, 833 
which overlaps accessible chromatin (DNase-seq, gray peaks). (b) Diagram of the Zfp410 gene 834 
trap allele. A targeting cassette including splice acceptor site upstream of LacZ was inserted 835 
into Zfp410 intron 5 thus disrupting full-length expression. Schema obtained along with mouse 836 
ES cells from EuMMCR, Germany. (c) Exon and domain structure of mouse Zfp410.  837 
 838 
Supplementary Figure 5. ZNF410 is dispensable for hematopoietic repopulation and 839 
erythropoiesis. CD34+ HSPCs from donor 3 were edited by RNP electroporation targeting 840 
ZNF410, BCL11A or ZBTB7A and infused to NBSGW mice or subject to in vitro erythroid 841 
differentiation. (a) Indel frequency at ZNF410, BCL11A and ZBTB7A was quantified in input 842 
cells 4 days after electroporation, and in engrafted total or sorted cells at bone marrow (BM) 843 
harvest. The percentage of frameshift alleles is represented in gray and the percentage of in-844 
frame alleles is represented in white. (b) Comparison of engraftment assessed by human 845 
CD45+ staining compared to total CD45+ cells in xenografts of ZNF410 (n=4), BCL11A (n=3) 846 
and ZBTB7A (n=3) edited and mock control (n=4) CD34+ HSPCs. Each symbol represents one 847 
mouse. (c, d) Erythroid maturation, evaluated based on CD71 and CD235a immunophenotype 848 
and enucleation frequency, was assessed on day 18 of in vitro erythroid culture. 849 
 850 
Supplementary Figure 6. Flow cytometry gating strategy for xenograft experiment. 851 
Hierarchy of FACS gates and representative plots for each gate are shown for a representative 852 
control (mock) transplanted bone marrow sample. The first gate was plotted to delineate the cell 853 
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population of interest (POI) and avoid debris. The second and third gates were plotted to 854 
exclude doublets. Values in plots are for respective gates. 855 
 856 
 857 
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Supplementary	Table	1
I Guide	RNAs
Gene/genomic	region gRNA	sequence
AAVS1 CUCCCUCCCAGGAUCCUCUC
Safe	sgRNA GUAAGCUUAAAACAUUAGUA
ZNF410 GUACAGUUGAAGGUUGUGAC
BCL11A gACAGAUGAUGAACCAGACCA
ZBTB7A GUAGGCGAAGUCCAUGAGCG
CHD4-proximal-gRNA-1 GUGCGGUGGGAUUUCCCGGC
CHD4-distal-gRNA-1 CGAGGCUGUGUCAGCGCCGC
CHD4-distal-gRNA-2 UUGGUCUGUGGGAUGGACAU
ZNF410-del-5Í-tgt1 ACGAGCATTTTCTCAAGCAC
ZNF410-del-3Í-tgt1 ATACCAGTAAAACTGAACCG
ZNF410-del-5Í-tgt2 CGGGTACTACCTAACCGAGG
ZNF410-del-3Í-tgt2 ATCTCAAAATGCGTATACT
II RT-qPCR	primers
Gene Forward	Primer Reverse	Primer
HBG TGGATGATCTCAAGGGCAC TCAGTGGTATCTGGAGGACA
HBB CTGAGGAGAAGTCTGCCGTTA AGCATCAGGAGTGGACAGAT
CHD4 CACCGAATCCTCAACCACAG TCTCCACATCCTCACTCTCC
mZfp410	exon	5	/	exon	6 CAGGAACTGGCCCATGAC GTCTTTTGGTTGCCCATCAC
mZfp410	exon	6	/	exon	7 CCAGCTCACTTCAAGTACCAC TGTCCTCATGTGCACCTTC
III PCR	primers
Name Sequence	5'-3'
CHD4-Outer-FP GGGCGTCTCTTTGGGAAC
CHD4-Outer-RP1 GGAGAACCAAGCAATGGAGAA
CHD4-Outer-RP2 GTGTTTCCCGAAGACCTGAA
CHD4-Inner-FP CCCATGGCCATCCCATAATAA
CHD4-Inner-RP AGGATGTGGGTAGGAGAGTAAA
ZNF410-outer-FP TGAGATCCCCACAGTACACTTG
ZNF410-outer-RP TGATAGCAAGAGTGCCTGCTC
ZNF410-inner-FP TTGGCAAACAGAACCACAAA
ZNF410-inner-RP CTTCCCCATCTTGTTTTCCA
LoxP-FP GTGAGCAGTGTAGAGGACTTTAT
LoxP-RP GATACTGCCCAAGCTGACTTA
IV PCR	primers	for	sgRNA	library	amplification	from	genomic	DNA
Step	1	PCR	
Name Sequence	5'-3'
PCR_1_FP AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG
PCR_1_RP CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCCC	
Step	2	PCR:	A	combination	of	one	of	the	following	forward	and	reverse	primers	were	used	for	each	sample	to	be	sequenced,	from	a	total	of	144	possible	unique	combinations.	
Name Sequence	5'-3'
Forward	primers
PCR_2_F01 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTtAAGTAGAGtcttgtggaaaggacgaaacaccg
PCR_2_F02 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTatACACGATCtcttgtggaaaggacgaaacaccg
PCR_2_F03 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTgatCGCGCGGTtcttgtggaaaggacgaaacaccg
PCR_2_F04 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTcgatCATGATCGtcttgtggaaaggacgaaacaccg
PCR_2_F05 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTtcgatCGTTACCAtcttgtggaaaggacgaaacaccg
PCR_2_F06 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTatcgatTCCTTGGTtcttgtggaaaggacgaaacaccg
PCR_2_F07 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTgatcgatAACGCATTtcttgtggaaaggacgaaacaccg
PCR_2_F08 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTcgatcgatACAGGTATtcttgtggaaaggacgaaacaccg
PCR_2_F09 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTacgatcgatAGGTAAGGtcttgtggaaaggacgaaacaccg
PCR_2_F10 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTtAACAATGGtcttgtggaaaggacgaaacaccg
PCR_2_F11 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTatACTGTATCtcttgtggaaaggacgaaacaccg
PCR_2_F12 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTgatAGGTCGCAtcttgtggaaaggacgaaacaccg
Reverse	primers
PCR_2_R01 CAAGCAGAAGACGGCATACGAGATAAGTAGAG	GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTtTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R02 CAAGCAGAAGACGGCATACGAGATACACGATCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R03 CAAGCAGAAGACGGCATACGAGATCGCGCGGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTgatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R04 CAAGCAGAAGACGGCATACGAGATCATGATCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTcgatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R05 CAAGCAGAAGACGGCATACGAGATCGTTACCAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTtcgatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R06 CAAGCAGAAGACGGCATACGAGATTCCTTGGTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTatcgatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R07 CAAGCAGAAGACGGCATACGAGATAACGCATTGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTgatcgatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R08 CAAGCAGAAGACGGCATACGAGATACAGGTATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTcgatcgatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R09 CAAGCAGAAGACGGCATACGAGATAGGTAAGGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTacgatcgatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R10 CAAGCAGAAGACGGCATACGAGATAACAATGGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTtTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R11 CAAGCAGAAGACGGCATACGAGATACTGTATCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTatTCTACTATTCTTTCCCCTGCACTGT
PCR_2_R12 CAAGCAGAAGACGGCATACGAGATAGGTCGCAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTgatTCTACTATTCTTTCCCCTGCACTGT
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